This site is intended for healthcare professionals outside the United States

62nd ASH ANNUAL MEETING
Expert-led conference insights in malignant and non-malignant hematology
Disease area
Content type
Watch On-Demand
Interactive panel discussion
Watch On-Demand
Interactive panel discussion

Professor Jane Apperley and colleagues discuss the latest data in CML

Date & Time:
17th December 9:30-10:30am (CET)
WATCH NOW
Prof. Jane Apperley (UK) chairs an expert panel to discuss the key data and findings from the CML scientific sessions at the 62nd ASH Annual Meeting. Register now to secure your place.
Disease area: CML
Watch On-Demand
Interactive panel discussion
Watch On-Demand
Interactive panel discussion

Professor John Gribben and colleagues discuss the latest data in MDS and AML

Date & Time:
16th December 3-4pm (CET)
WATCH NOW
Prof. John Gribben (UK) chairs an expert panel to discuss the key data and findings from the MDS/AML scientific sessions at the 62nd ASH Annual Meeting. Register now to secure your place.
Disease area: MDS/AML
Watch On-Demand
Interactive panel discussion
Watch On-Demand
Interactive panel discussion

Professor Martin Dreyling and colleagues discuss the latest data in FL, DLBCL and MCL

Date & Time:
14th December 11am-12pm (CET)
WATCH NOW
Prof. Martin Dreyling (Germany) chairs an expert panel to discuss the key data and findings from the FL/DLBCL/MCL scientific sessions at the 62nd ASH Annual Meeting. Register now to secure your place.
Disease area: FL/DLBCL/MCL
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: GvHD

Published:
30th March 2021
Speaker: Jacopo Mariotti
Speaker Affiliation: Bone Marrow Transplantation Unit, Humanitas Research Hospital, Milan, Italy
LISTEN NOW
Dr. Jacopo Mariotti discusses his top highlights of the data and findings from the GvHD scientific sessions at the ASH 2020.
Disease area: GvHD
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: MDS/AML

Published:
22nd March 2021
Speaker: António Almeida
Speaker Affiliation: Hospital da Luz, Lisbon, Portugal
LISTEN NOW
Professor António Almeida discusses his top highlights of the data and findings from the MDS/AML scientific sessions at the ASH 2020.
Disease area: MDS/AML
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: Sickle Cell Anemia

Published:
2nd March 2021
Speaker: Giovanna Russo & Raffaella Colombatti
Speaker Affiliation: Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy (GR); Department of Women’s and Children’s Health, University of Padova, Padova, Italy (RC)
LISTEN NOW
Professor Giovanna Russo and Professor Raffaella Colombatti discuss their top highlights of the data and findings from the Sickle cell scientific sessions at the ASH 2020.
Disease area: Sickle Cell
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: Immune Thrombocytopenia

Published:
13th March 2021
Speaker: Sabine Eichinger & Johanna Gebhart
Speaker Affiliation: Department of Medicine, Medical University of Vienna, Vienna, Austria (SE, JG)
LISTEN NOW
Dr. Sabine Eichinger and Dr. Johanna Gebhart discuss their top highlights of the data and findings from the ITP scientific sessions at the ASH 2020.
Disease area: ITP
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: FL/DLBCL

Published:
9th March 2021
Speaker: Christopher Paul Fox & Wendy Osborne
Speaker Affiliation: Nottingham University Hospitals NHS Trust, Nottingham, UK (CP); Freeman Hospital and Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle, UK (WO)
LISTEN NOW
Dr. Christopher Fox and Dr. Wendy Osborne discuss their top highlights of the data and findings from the FL/DLBCL scientific sessions focusing on CAR-T cell therapies at the ASH 2020.
Disease area: FL/DLBCL
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: MPN

Published:
13th March 2021
Speaker: Massimo Breccia
Speaker Affiliation: Department of Translational and Precision Medicine, University of Rome, Rome, Italy
LISTEN NOW
Dr. Massimo Breccia discusses his top highlights of the data and findings from the MPN scientific sessions at the ASH 2020.
Disease area: MPN
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: CML

Published:
15th March 2021
Speaker: Massimo Breccia
Speaker Affiliation: Department of Translational and Precision Medicine, University of Rome, Rome, Italy
LISTEN NOW
Dr. Massimo Breccia discusses his top highlights of the data and findings from the CML scientific sessions at the ASH 2020.
Disease area: CML
Read Now
News
Read Now
News

Risk factors for intracranial hemorrhage in older ITP patients identified

Published:
February 3rd 2021
Speaker: Shreeya Nanda
READ NOW
Chinese researchers have identified predictive and prognostic factors for intracranial hemorrhage in immune thrombocytopenia patients older than 60 years of age.
Disease area: ITP
Read Now
News
Read Now
News

Sutimlimab elicits ‘sustained’ responses in some chronic ITP patients

Published:
February 3rd 2021
Speaker: Shreeya Nanda
READ NOW
Extended follow-up of a phase 1b trial shows that responses to sutimlimab are maintained after more than a year of treatment in a subset of chronic immune thrombocytopenia patients with an inadequate response to multiple previous therapies.
Disease area: ITP
Watch Now
Expert interview
Watch Now
Expert interview

Gian Luca Forni - Outcomes of COVID-19 in people with hemoglobinopathies reported

Published:
21st January 2021
Speaker: Gian Luca Forni
Speaker Affiliation: Ospedale Galliera, Genoa, Italy
WATCH NOW
Gian Luca Forni shares data on the prevalence and outcomes of SARS-CoV-2 infection in Italian patients with thalassemia or sickle cell disease.
Disease area: Sickle Cell
Read Now
News
Read Now
News

Radiotherapy plus cyclophosphamide–tacrolimus ‘feasible’ alloHCT regimen for AML

Published:
21st January 2021
Speaker: Lynda Williams
READ NOW
A chemotherapy-free allogeneic hematopoietic transplantation regimen is feasible and could reduce the risk of graft-versus-host disease and relapse in patients with acute myeloid leukemia… (read more)
Disease area: GvHD
Read Now
News
Read Now
News

Blood cell subpopulations show biomarker potential in pediatric chronic GvHD

Published:
21st January 2021
Speaker: Lucy Piper
READ NOW
Identifying certain subpopulations of T and natural killer cells could help to diagnose pediatric chronic GvHD at the onset of the disorder… (read more)
Disease area: GvHD
Watch Now
Expert interview
Watch Now
Expert interview

Rick Kapur - Understanding platelet count and bleeding outcomes in ITP

Published:
21st January 2021
Speaker: Rick Kapur
Speaker Affiliation: Sanquin Research, and Landsteiner Laboratory, Amsterdam, The Netherlands
WATCH NOW
Rick Kapur offers insights on the findings of a literature review looking at variability in platelet count and bleeding outcomes in patients with immune thrombocytopenia and the need for standardization.
Disease area: ITP
Read Now
News
Read Now
News

Rilzabrutinib achieves ‘durable response’ for heavily pretreated ITP patients

Published:
21st December 2020
Speaker: Lynda Williams
READ NOW
Early results for the oral Bruton tyrosine kinase (BTK) inhibitor rilzabrutinib support its use in patients with relapsed or refractory immune thrombocytopenia (ITP). David Kuter, from Massachusetts... (read more)
Disease area: ITP
Watch Now
Expert interview
Watch Now
Expert interview

Delphine Rea - CANDID study characterizes COVID-19 risk in CML patients

Published:
21st December 2020
Speaker: Delphine Rea
Speaker Affiliation: Hôpital Saint-Louis, Paris, France
WATCH NOW
Delphine Rea presents the International Chronic Myeloid Leukemia Foundation’s CANDID study findings showing that age is the most significant risk factor for COVID-19 mortality in CML patients.
Disease area: MPN - CML
Read Now
News
Read Now
News

Itacitinib plus CNI-based regimen shows potential for GvHD prevention after alloHCT

Published:
21st January 2021
Speaker: Lynda Williams
READ NOW
Findings from a proof-of-principle study indicate that use of the JAK1 inhibitor itacitinib alongside a calcineurin inhibitor may help prevent GvHD after transplantation… (read more)
Disease area: GvHD
Watch Now
Expert interview
Watch Now
Expert interview

Naranie Shanmuganathan - Cancer-related mutations linked to poor CML prognosis

Published:
3rd February 2021
Speaker: Naranie Shanmuganathan
Speaker Affiliation: Royal Adelaide Hospital, Australia
WATCH NOW
Naranie Shanmuganathan describes the characterization of cancer-related mutations at time of first-line treatment initiation for chronic myeloid leukemia and their relationship to patient prognosis.
Disease area: MPN-CML
Watch Now
Expert interview
Watch Now
Expert interview

Mohamad Mohty - ROCKstar: Belumosudil shows potential for refractory, advanced GvHD

Published:
16th December 2020
Speaker: Mohamad Mohty
Speaker Affiliation: Hôpital Saint-Antoine, Paris, France
WATCH NOW
Mohamad Mohty highlights the findings from the ROCKstar study showing a good response to belumosudil among heavily pretreated patients with chronic graft-versus-host disease.
Disease area: GvHD
Watch Now
Expert interview
Watch Now
Expert interview

Selim Corbacioglu - CRISPR-Cas9 gene editing shows sickle cell disease promise

Published:
16th December 2020
Speaker: Selim Corbacioglu
Speaker Affiliation: University of Regensburg, Germany
WATCH NOW
Selim Corbacioglu discusses the CLIMB SCD-121 and CLIMB THAL-111 trials demonstrating the potential of CTX001, a novel CRISPR-Cas9 gene editing therapy, for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia, respectively.
Disease area: Sickle Cell
Watch Now
Expert interview
Watch Now
Expert interview

Shehu Umar Abdullahi - SPRINT supports low-dose hydroxyurea for secondary stroke prevention in SCD

Published:
14th December 2020
Speaker: Shehu Umar Abdullahi
Speaker Affiliation: Bayero University/Aminu Kano Teaching hospital, Kano, Nigeria
WATCH NOW
Shehu Umar Abdullahi takes us through the SPRINT study establishing fixed low-dose hydroxyurea with biannual complete blood counts as an appropriate strategy in low-income settings for preventing secondary strokes in children with sickle cell disease.
Disease area: Sickle Cell
Watch Now
Expert interview
Watch Now
Expert interview

Maria Lozano - FLIGHT trial: Mycophenolate plus steroid a possible first-line option for ITP

Published:
14th December 2020
Speaker: Maria Lozano
Speaker Affiliation: University of Murcia, Spain
WATCH NOW
Maria Lozano comments on the trial showing the benefits of combining mycophenolate with corticosteroid in the first-line setting and outlines what this might mean for early intensive therapy in immune thrombocytopenia.
Disease area: ITP
Watch Now
Expert interview
Watch Now
Expert interview

Françoise Bernaudin - Study sheds light on intra- and extracranial arteriopathy in sickle cell disease

Published:
14th December 2020
Speaker: Françoise Bernaudin
Speaker Affiliation: CHIC Hospital, Créteil, France
WATCH NOW
Françoise Bernaudin reports on their research evaluating the incidence of intra- and extracranial cerebral arteriopathy, and associated risk factors, in a longitudinal, pediatric sickle cell disease cohort.
Disease area: Sickle Cell
Watch Now
Expert interview
Watch Now
Expert interview

Rafael Daltro De Oliveira - IFN discontinuation may be feasible for MPN patients in complete hematologic remission

Published:
14th December 2020
Speaker: Rafael Daltro De Oliveira
Speaker Affiliation: Hôpital Saint-Louis, Paris, France
WATCH NOW
Rafael Daltro de Oliveira explains why his research indicates physicians may consider discontinuing interferon-alpha therapy for myeloproliferative neoplasm patients in hematologic remission.
Disease area: MPN
Watch Now
Expert interview
Watch Now
Expert interview

Claire Harrison - Tamoxifen may reduce mutant allele burden for myeloproliferative neoplasm patients

Published:
14th December 2020
Speaker: Claire Harrison
Speaker Affiliation: Guy's and St Thomas' NHS Foundation Trust, London, UK
WATCH NOW
Claire Harrison outlines the findings of the TAMARIN study, an investigation of tamoxifen as a means of reducing driver mutation allele burden in patients with myeloproliferative neoplasms.
Disease area: MPN
Watch Now
Expert interview
Watch Now
Expert interview

Jyoti Nangalia - Myeloproliferative neoplasm development begins early in life

Published:
14th December 2020
Speaker: Jyoti Nangalia
Speaker Affiliation: Wellcome Sanger Institute, Hinxton, UK
WATCH NOW
Jyoti Nangalia explains how their study of driver mutations has revealed that myeloproliferative neoplasms may begin decades before diagnosis.
Disease area: MPN
Watch Now
Expert interview
Watch Now
Expert interview

Andreas Hochhaus - ASCEMBL findings support STAMP inhibitor for heavily pretreated CML

Published:
9th December 2020
Speaker: Andreas Hochhaus
Speaker Affiliation: Klinik für Innere Medizin II, Jena, Germany
WATCH NOW
Andreas Hochhaus reports the phase 3 trial findings for the first-in-class STAMP inhibitor asciminib versus bosutinib in patients with chronic myeloid leukemia who have previously received two or more tyrosine kinase inhibitors.
Disease area: MPN - CML
Watch Now
Expert interview
Watch Now
Expert interview

Binta Jibir - Low-dose hydroxyurea an option for primary stroke prevention in sickle cell disease

Published:
7th December 2020
Speaker: Binta Jibir
Speaker Affiliation: Hasiya Bayero Specialist Hospital, Kano, Nigeria
WATCH NOW
Binta Jibir outlines the key findings of the Nigerian SPRING trial showing no significant difference in the incidence of stroke with low- versus moderate-dose hydroxyurea in children with sickle cell disease at risk for primary stroke.
Disease area: Sickle Cell
Watch Now
Expert interview
Watch Now
Expert interview

Stéphanie Forté - Educational bias in sickle cell disease cognitive screening tools highlighted

Published:
7th December 2020
Speaker: Stéphanie Forté
Speaker Affiliation: Centre hospitalier de l'Université de Montréal, Quebec, Canada
WATCH NOW
Stéphanie Forté presents their research showing the educational bias in neurocognitive screening tools for adults with sickle cell disease and suggests strategies to mitigate this bias.
Disease area: Sickle Cell
Watch Now
Expert interview
Watch Now
Expert interview

José Miguel Alvarez Blanco - Accessory spleen extraction has a place in refractory cytopenia treatment

Published:
7th December 2020
Speaker: José Miguel Alvarez Blanco
Speaker Affiliation: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
WATCH NOW
José Miguel Alvarez Blanco discusses his findings showing accessory spleen extraction could be an effective lower-cost strategy to consider for the treatment of refractory immune cytopenias.
Disease area: ITP
Watch Now
Expert interview
Watch Now
Expert interview

Florent Malard - Support for fecal microbiota transfer in steroid-resistant intestinal GvHD

Published:
7th December 2020
Speaker: Florent Malard
Speaker Affiliation: Hopital Saint Antoine, Paris, France
WATCH NOW
Florent Malard shares his findings on MaaT013, a microbiota biotherapeutic, for the treatment of intestinal acute graft-versus-host disease in heavily pretreated and immunocompromised patients.
Disease area: GvHD
Watch Now
Expert interview
Watch Now
Expert interview

Robert Zeiser - REACH3: Ruxolitinib second-line standard of care potential in chronic GvHD

Published:
7th December 2020
Speaker: Robert Zeiser
Speaker Affiliation: University Medical Center, Freiburg, Germany
WATCH NOW
Robert Zeiser reports on the phase 3 trial of ruxolitinib showing its benefit in patients with steroid-refractory or dependent chronic graft-versus-host disease.
Disease area: GvHD

Registration.

After registering your interest we’ll keep you posted on:

  • Our expert faculty
  • Agenda of events and how you can get involved
  • * Required
  • This program is not available in the United States. Please tick the box to confirm you are a healthcare professional outside the United States.

Funding.

The content and faculty for this program have been independently developed and/or selected by Springer Healthcare. Novartis Pharmaceutical Corporation provided unconditional funding and as such had no involvement with, or influence on the content and selection of faculty. The content is not intended for use by healthcare professionals in the US. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not reflect the views of Springer Healthcare. Springer Healthcare assumes no responsibility for any injury or damage to persons or property arising out of, or related to, any use of the material or to any errors or omissions. Please consult the latest prescribing information from the manufacturer for any products mentioned in this material.

Conference insights from
62nd ASH ANNUAL MEETING